...
首页> 外文期刊>British Journal of Cancer >Modification of CCNU pharmacokinetics by misonidazole—a major mechanism of chemosensitization in mice
【24h】

Modification of CCNU pharmacokinetics by misonidazole—a major mechanism of chemosensitization in mice

机译:米诺达唑对CCNU药代动力学的修饰-小鼠化学增敏的主要机制

获取原文

摘要

We have investigated the effect of misonidazole (MISO) on the pharmacokinetics of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in mice. CCNU and its monohydroxylated metabolites were measured using a high performance liquid chromatography (HPLC) method. In the absence of MISO the plasma disappearance of CCNU was biphasic with a t 1/2 alpha of 2.3 min and a t 1/2 beta of 53 min. The monohydroxylated metabolites of CCNU also followed biphasic clearance kinetics. A large single dose of MISO (0.5 mg g-1), given i.p. 30 min prior to CCNU, prolonged the t 1/2 alpha by a factor of 2.6 but had no effect on t 1/2 beta. In addition, the apparent volume of distribution was decreased by a factor of 1.6. Consequently, the plasma area under the curve (AUC0 - infinity) was increased by a factor of 1.7 for CCNU and by a factor of 2.0 for total nitrosourea (CCNU + monohydroxylated metabolites). The effects of MISO on CCNU kinetics were dependent on MISO dose and plasma concentration and on the interval between MISO and CCNU administration. The concentration of CCNU was measured in 4 tumours: the KHT, RIF-1 and EMT6 mouse tumours, and the HT29 xenograft. For all 4 tumours, 0.5 mg g-1 MISO raised the tumour concentrations of CCNU and total nitrosourea by a considerable amount (2-2.5 times). More detailed studies in the KHT tumour demonstrated that there was a significant lag period before peak tumour CCNU concentrations were reached, and that MISO increased the peak concentrations by a factor of about 2.4. In contrast, there was no such lag period for the plasma and MISO did not increase the plasma peak CCNU concentrations. These data strongly suggest that modification of the pharmacokinetics may be a major contributory factor in the enhancement of CCNU cytotoxicity by large single doses of MISO in vivo.
机译:我们已经研究了米索硝唑(MISO)对小鼠1-(2-氯乙基)-3-环己基-1-亚硝基脲(CCNU)的药代动力学的影响。使用高效液相色谱(HPLC)方法测量CCNU及其单羟基代谢产物。在没有MISO的情况下,CCNU的血浆消失是双相的,t 1/2 alpha为2.3分钟,t 1/2 beta为53分钟。 CCNU的单羟基化代谢物也遵循双相清除动力学。腹膜内给予大剂量的MISO(0.5 mg g-1)。在CCNU之前30分钟,t 1/2 alpha延长了2.6倍,但对t 1/2 beta没有影响。此外,表观分布体积减少了1.6倍。因此,曲线下的血浆面积(AUC0-无穷大)对于CCNU增加了1.7倍,对于总亚硝基脲(CCNU +单羟基化代谢物)增加了2.0倍。 MISO对CCNU动力学的影响取决于MISO剂量和血浆浓度以及MISO和CCNU给药间隔。在4种肿瘤中测量CCNU的浓度:KHT,RIF-1和EMT6小鼠肿瘤以及HT29异种移植物。对于所有4种肿瘤,0.5 mg g-1 MISO可使CCNU和总亚硝基脲的肿瘤浓度显着增加(2-2.5倍)。在KHT肿瘤中进行的更详细的研究表明,在达到峰值肿瘤CCNU浓度之前,存在明显的滞后时间,并且MISO将峰值浓度提高了约2.4倍。相反,血浆没有这样的滞后时间,MISO不会增加血浆峰值CCNU浓度。这些数据强烈表明,药代动力学的修饰可能是体内大剂量单次使用MISO增强CCNU细胞毒性的主要促成因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号